KRAS and cancer: These challenges apparently do not exist for the widely used epidermal growth factor receptor inhibitors and the recent ground-breaking KRAS-G12C inhibitors (Canon et al., 2019) since, according to The Cancer Genome Atlas Program Pan-Cancer Altas Studies, their applicable mutations are predominately found in one cancer type (lung adenocarcinoma) and clustered in one or a few codons of their encoding genes.